

# Maria P Sormani

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/905467/ maria-p-sormani-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

390  
papers

18,125  
citations

72  
h-index

118  
g-index

415  
ext. papers

21,925  
ext. citations

5.9  
avg, IF

6.63  
L-index

#	Paper	IF	Citations
390	Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 57, 103358	4	4
389	COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	17
388	A real-world study of alemtuzumab in a cohort of Italian patients. <i>European Journal of Neurology</i> , <b>2022</b> , 29, 257-266	6	2
387	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.. <i>Multiple Sclerosis Journal</i> , <b>2022</b> , 13524585211069068	5	1
386	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.. <i>Lancet Neurology, The</i> , <b>2022</b> , 21, 246-257 <sup>24.1</sup>	24.1	16
385	Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.. <i>Multiple Sclerosis Journal</i> , <b>2022</b> , 13524585221089534	5	0
384	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.. <i>EBioMedicine</i> , <b>2022</b> , 80, 104042	8.8	3
383	Is the effect of drugs in progressive MS only due to an effect on inflammation? A subgroup meta-analysis of randomised trials.. <i>Multiple Sclerosis Journal</i> , <b>2022</b> , 13524585221094944	5	0
382	A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 103909	4	0
381	Retinal Hyperreflecting Foci Associate With Cortical Pathology in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9, e1180	9.1	2
380	The role of nutritional factors during adolescence in multiple sclerosis onset: a population-based incident case-control study. <i>Nutritional Neuroscience</i> , <b>2021</b> , 24, 500-507	3.6	6
379	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , <b>2021</b> ,	6	1
378	Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211052400	5	
377	The MuSC-19 study: The Egyptian cohort. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 56, 103324	4	3
376	Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. <i>Lancet Neurology, The</i> , <b>2021</b> , 20, 917-929 <sup>24.1</sup>	24.1	9
375	Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a. <i>Neurology</i> , <b>2021</b> , 96, e214-e227 <sup>6.5</sup>	6.5	2
374	COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 2126-2136	5	16

373	Dedicated 3D-T2-STIR-ZOOMit Imaging Improves Demyelinating Lesion Detection in the Anterior Visual Pathways of Patients with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , <b>2021</b> , 42, 1061-1068	4.4	0
372	MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 49, 102790	4	1
371	Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211005654	5.0	4
370	Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 147, 1217-1225	11.5	30
369	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. <i>Journal of the Neurological Sciences</i> , <b>2021</b> , 424, 117385	3.2	2
368	Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211010294	5.5	10
367	Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211019650	5	1
366	The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 52, 102968	4	15
365	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211024997	5	13
364	Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series. <i>Neurology</i> , <b>2021</b> , 97, e890-e901	6.5	4
363	Patient@ point of view on the use of telemedicine in multiple sclerosis: a web-based survey. <i>Neurological Sciences</i> , <b>2021</b> , 1	3.5	1
362	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 695-705	5	4
361	Prevalence of disability improvement as a potential outcome for multiple sclerosis trials. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 706-711	5	3
360	Rapid eye movement sleep behavior disorder: A proof-of-concept neuroprotection study for prodromal synucleinopathies. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 1210-1217	6	2
359	Comparative effectiveness of rituximab in multiple sclerosis. <i>Nature Reviews Neurology</i> , <b>2021</b> , 17, 3-4	15	2
358	Digital work engagement among Italian neurologists. <i>Therapeutic Advances in Chronic Disease</i> , <b>2021</b> , 12, 20406223211029616	4.9	5
357	Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> ,	6.5	11
356	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , <b>2021</b> , 89, 780-789	9.4	189

355	Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalization. <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 623-630	5.3	4
354	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211035318	5	21
353	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 1738-1744	5.3	36
352	Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211032348	5	3
351	Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 3547-3556	3.7	11
350	Clinical efficacy of eucaloric ketogenic nutrition in the COVID-19 cytokine storm: A retrospective analysis of mortality and intensive care unit admission. <i>Nutrition</i> , <b>2021</b> , 89, 111236	4.8	9
349	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. <i>EBioMedicine</i> , <b>2021</b> , 72, 103581	8.8	74
348	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology</i> , <b>2021</b> , 3, e690-e697	14.2	38
347	Coronavirus disease 2019 in Latin American patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 55, 103173	4	5
346	Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal. <i>Nature Reviews Neurology</i> , <b>2021</b> , 17, 185-192	15	6
345	Paediatric multiple sclerosis: a lesson from TERIKIDS. <i>Lancet Neurology</i> , <b>2021</b> , 20, 971-973	24.1	0
344	Multiple Sclerosis in the Campania Region (South Italy): Algorithm Validation and 2015-2017 Prevalence. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	5
343	Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 76, 31-35	3.9	178
342	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 1352458520924595	5	6
341	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 1352458520925369	5	14
340	Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event. <i>Annals of Neurology</i> , <b>2020</b> , 88, 407-417	9.4	35
339	Combining biomarkers to profile multiple sclerosis patients. <i>Nature Reviews Neurology</i> , <b>2020</b> , 16, 463-464	5	0
338	Wide Cytokine Analysis in Cerebrospinal Fluid at Diagnosis Identified CCL-3 as a Possible Prognostic Factor for Multiple Sclerosis. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 174	8.4	3

337	First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 42, 102059	4	4
336	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. <i>Neurology</i> , <b>2020</b> , 95, e1027-e1040	6.5	11
335	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. <i>Nature Reviews Neurology</i> , <b>2020</b> , 16, 171-182	15	68
334	An Italian programme for COVID-19 infection in multiple sclerosis. <i>Lancet Neurology, The</i> , <b>2020</b> , 19, 481-482	4.1	143
333	A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis. <i>Neurology and Therapy</i> , <b>2020</b> , 9, 359-374	4.6	6
332	Effects of aging on finger movements in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 37, 101449	4	2
331	Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1828-1836	5	4
330	An "all-wheel drive" proposal to accelerate clinical research in common and rare neurological diseases. <i>Neurological Sciences</i> , <b>2020</b> , 41, 789-793	3.5	
329	Overview of Differences and Similarities of Published Mixed Treatment Comparisons on Pharmaceutical Interventions for Multiple Sclerosis. <i>Neurology and Therapy</i> , <b>2020</b> , 9, 335-358	4.6	2
328	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology, The</i> , <b>2020</b> , 19, 988-997	24.1	28
327	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. <i>JAMA Neurology</i> , <b>2020</b> , 77, 1496-1503	17.2	11
326	Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 45, 102359	4	6
325	Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e016309	6	7
324	Assessing upper limb function in multiple sclerosis using an engineered glove. <i>European Journal of Neurology</i> , <b>2020</b> , 27, 2561-2567	6	1
323	Cladribine vs other drugs in MS: Merging randomized trial with real-life data. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2020</b> , 7,	9.1	14
322	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. <i>PLoS ONE</i> , <b>2020</b> , 15, e0237831	3.7	62
321	A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1064-1073	5	6
320	Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1227-1236	5	8

319	Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1519-1531	5	19
318	Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 283-306	4.4	61
317	Real-world studies provide reliable comparisons of disease modifying therapies in MS - No. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 161-162	5	1
316	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?. <i>Neurotherapeutics</i> , <b>2020</b> , 17, 200-207	4	24
315	Comparison of Placebos and Propensity Score Adjustment in Multiple Sclerosis Nonrandomized Studies. <i>JAMA Neurology</i> , <b>2020</b> , 77, 902-903	17.2	1
314	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia <b>2020</b> , 15, e0237831		
313	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia <b>2020</b> , 15, e0237831		
312	Revised upper limb module for spinal muscular atrophy: 12 month changes. <i>Muscle and Nerve</i> , <b>2019</b> , 59, 426-430	3.4	39
311	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , <b>2019</b> , 18, 185-197	24.1	74
310	Lifespan normative data on rates of brain volume changes. <i>Neurobiology of Aging</i> , <b>2019</b> , 81, 30-37	5.6	24
309	Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study. <i>Journal of Neurology</i> , <b>2019</b> , 266, 2440-2446	5.5	13
308	Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data. <i>BMC Medicine</i> , <b>2019</b> , 17, 113	11.4	5
307	Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. <i>Annals of Clinical and Translational Neurology</i> , <b>2019</b> , 6, 1081-1089	5.3	28
306	MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. <i>Trials</i> , <b>2019</b> , 20, 263	2.8	41
305	Different MRI patterns in MS worsening after stopping fingolimod. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6, e566	9.1	13
304	Classification criteria for autoinflammatory recurrent fevers. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1025-1032	2.4	159
303	Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: a large-scale, single-centre study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2019</b> , 5, 2055217319843673	2	1
302	How much do periventricular lesions assist in distinguishing migraine with aura from CIS?. <i>Neurology</i> , <b>2019</b> , 92, e1739-e1744	6.5	8

301	Longitudinal Characterization of Cortical Lesion Development and Evolution in Multiple Sclerosis with 7.0-T MRI. <i>Radiology</i> , <b>2019</b> , 291, 740-749	20.5	32
300	Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1263-1272	5	26
299	Subclinical motor impairment assessed with an engineered glove correlates with magnetic resonance imaging tissue damage in radiologically isolated syndrome. <i>European Journal of Neurology</i> , <b>2019</b> , 26, 162-167	6	13
298	Single-Port Versus Conventional Laparoscopic Cholecystectomy: Better Cosmesis at the Price of an Increased Incisional Hernia Rate?. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , <b>2019</b> , 29, 1163-1167	2.1	4
297	Head-to-head drug comparisons in multiple sclerosis: Urgent action needed. <i>Neurology</i> , <b>2019</b> , 93, 793-809	5	13
296	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 36, 101430	4	14
295	BEAM Vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society. <i>Blood</i> , <b>2019</b> , 134, 3313-3323	2.2	13
294	Multiple sclerosis: clinical trial design 2019. <i>Current Opinion in Neurology</i> , <b>2019</b> , 32, 358-364	7.1	8
293	Laparoscopic Splenectomy Versus Open Splenectomy In Massive and Giant Spleens: Should we Update the 2008 EAES Guidelines?. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , <b>2019</b> , 29, 178-181	1.3	11
292	Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. <i>Neurology</i> , <b>2019</b> , 92, 180-192	6.5	50
291	Increased incidence of axonal Guillain-Barré syndrome in La Spezia area of Italy: A 13-year follow-up study. <i>Journal of the Peripheral Nervous System</i> , <b>2019</b> , 24, 80-86	4.7	8
290	Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 261-267	5.5	15
289	Learning ability correlates with brain atrophy and disability progression in RRMS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 38-43	5.5	11
288	Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 541-553	5	22
287	Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 217-223	5	4
286	Cognitive clinico-radiological paradox in early stages of multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , <b>2018</b> , 5, 81-91	5.3	17
285	ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , <b>2018</b> , 25, 215-237	6	96
284	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 96-120	5	286

283	Estimates of age-dependent cutoffs for pathological brain volume loss using SIENA/FSL-a longitudinal brain volumetry study in healthy adults. <i>Neurobiology of Aging</i> , <b>2018</b> , 65, 1-6	5.6	17
282	Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. <i>Annals of Clinical and Translational Neurology</i> , <b>2018</b> , 5, 346-356	5.3	13
281	Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL. <i>Journal of Neurology</i> , <b>2018</b> , 265, 1158-1165	5.5	9
280	Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 222-226	5	33
279	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 642-652	5	18
278	Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. <i>PLoS ONE</i> , <b>2018</b> , 13, e0199223	3.7	28
277	Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 245-255	5.5	28
276	Authors' Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl. <i>Neurology and Therapy</i> , <b>2018</b> , 7, 391-393	4.6	
275	A prospective comparative trial of adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts (ASTOUND-2). <i>European Journal of Cancer</i> , <b>2018</b> , 104, 39-46	7.5	47
274	Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas. <i>Annals of Neurology</i> , <b>2018</b> , 84, 621-625	9.4	12
273	Neurofilaments as biomarkers in neurological disorders. <i>Nature Reviews Neurology</i> , <b>2018</b> , 14, 577-589	15	627
272	068 Evaluation of the long-term treatment effect of teriflunomide on cognitive outcomes and association with brain volume change: data from temso and its extension study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, A28.1-A28	5.5	2
271	Clinical activity after fingolimod cessation: disease reactivation or rebound?. <i>European Journal of Neurology</i> , <b>2018</b> , 25, 1270-1275	6	39
270	Subgroup analysis in MS trials. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 34-35	5	2
269	Reporting treatment outcomes in observational data: A fine balance. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 21-22	5	7
268	Estimating a treatment effect: Choosing between relative and absolute measures. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 197-200	5	2
267	NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 201-204	5	55
266	Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. <i>Multiple Sclerosis and Related Disorders</i> , <b>2017</b> , 12, 70-78	4	64



265	Treatment decisions in multiple sclerosis - insights from real-world observational studies. <i>Nature Reviews Neurology</i> , <b>2017</b> , 13, 105-118	15	126
264	Indirect comparisons of treatment effects: Network meta-analyses. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 510-512	5	1
263	No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. <i>Neurology</i> , <b>2017</b> , 88, 1144-1152	6.5	43
262	Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 378-381	5	7
261	The most frequently asked question to a statistician: The sample size. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 644-646	5	3
260	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. <i>JAMA Neurology</i> , <b>2017</b> , 74, 459-469	17.2	147
259	Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1757-1761	5	32
258	Approved drugs for multiple sclerosis: the challenge of choice. <i>Lancet Neurology, The</i> , <b>2017</b> , 16, 252-253	24.1	7
257	Three-Dimensional Shape and Surface Features Distinguish Multiple Sclerosis Lesions from Nonspecific White Matter Disease. <i>Journal of Neuroimaging</i> , <b>2017</b> , 27, 613-619	2.8	13
256	Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis. <i>Neurology</i> , <b>2017</b> , 88, 2115-2122	6.5	93
255	Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. <i>Nature Reviews Neurology</i> , <b>2017</b> , 13, 391-405	15	128
254	Why non-inferiority is more challenging than superiority?. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 790-791	5	2
253	MRI FLAIR lesion segmentation in multiple sclerosis: Does automated segmentation hold up with manual annotation?. <i>NeuroImage: Clinical</i> , <b>2017</b> , 13, 264-270	5.3	48
252	Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2017</b> , 4, e397	9.1	14
251	Steroid treatment of acute graft-host disease grade I: a randomized trial. <i>Haematologica</i> , <b>2017</b> , 102, 2125-2133	6.6	13
250	To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , <b>2017</b> , 82, 697-705	9.4	30
249	Clinical trial design for progressive MS trials. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1642-1648	5	8
248	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. <i>Brain</i> , <b>2017</b> , 140, 2814-2819	11.2	38

247	Quantitative assessment of finger motor performance: Normative data. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186524	3.7	11
246	Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0183957	3.7	20
245	Maturational Trajectory of Processing Speed Performance in Pediatric Multiple Sclerosis. <i>Developmental Neuropsychology</i> , <b>2017</b> , 42, 299-308	1.8	3
244	A Comprehensive Review on Copemyl. <i>Neurology and Therapy</i> , <b>2017</b> , 6, 161-173	4.6	6
243	Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study. <i>Neurology</i> , <b>2017</b> , 89, 2222-2229	6.5	34
242	Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials. <i>Neurotherapeutics</i> , <b>2017</b> , 14, 924-933	6.4	16
241	Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2017</b> , 4, e379	9.1	9
240	Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 656-664	5	29
239	Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach. <i>European Journal of Neurology</i> , <b>2017</b> , 24, 292-301	6	20
238	Enteric Microbiome Markers as Early Predictors of Clinical Outcome in Allogeneic Hematopoietic Stem Cell Transplant: Results of a Prospective Study in Adult Patients. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx215	1	23
237	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , <b>2017</b> , 140, 2776-2796	11.2	102
236	Cerebellar volume as imaging outcome in progressive multiple sclerosis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0176519	3.7	17
235	MRI in the evaluation of pediatric multiple sclerosis. <i>Neurology</i> , <b>2016</b> , 87, S88-96	6.5	33
234	A practical review of the neuropathology and neuroimaging of multiple sclerosis. <i>Practical Neurology</i> , <b>2016</b> , 16, 279-87	2.4	23
233	Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy. <i>Neuromuscular Disorders</i> , <b>2016</b> , 26, 576-83	2.9	36
232	Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 1906-1912	27.4	153
231	Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. <i>Annals of Neurology</i> , <b>2016</b> , 79, 288-94	9.4	96
230	Assessing response to interferon- $\beta$ in a multicenter dataset of patients with MS. <i>Neurology</i> , <b>2016</b> , 87, 134-40	6.5	74

229	Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 782-91	5	33
228	The challenge of comorbidity in clinical trials for multiple sclerosis. <i>Neurology</i> , <b>2016</b> , 86, 1437-1445	6.5	30
227	Recommendations for observational studies of comorbidity in multiple sclerosis. <i>Neurology</i> , <b>2016</b> , 86, 1446-1453	6.5	51
226	Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. <i>Neuromuscular Disorders</i> , <b>2016</b> , 26, 126-31	2.9	105
225	Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 6, 57-63	4	30
224	Adjunct Screening With Tomosynthesis or Ultrasound in Women With Mammography-Negative Dense Breasts: Interim Report of a Prospective Comparative Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1882-1888	2.2	136
223	Inclusion of brain volume loss in a revised measure of $\Delta$ o evidence of disease activity (NEDA-4) in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1297-305	5	169
222	Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 93-9	5.5	125
221	The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0149685	3.7	19
220	Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0151445	3.7	22
219	Clinical epidemiology of amyotrophic lateral sclerosis in Liguria, Italy: An update of LIGALS register. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , <b>2016</b> , 17, 535-542	3.6	24
218	Brain health: time matters in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 9 Suppl 1, S5-S48	4	189
217	Diagnostic performance of contrast-enhanced spectral mammography: Systematic review and meta-analysis. <i>Breast</i> , <b>2016</b> , 28, 13-9	3.6	82
216	Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 7, 98-101	4	17
215	Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1423-30	5	39
214	Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test. <i>Neuromuscular Disorders</i> , <b>2015</b> , 25, 749-53	2.9	35
213	Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 471-82	15	272
212	Optimizing therapy early in multiple sclerosis: An evidence-based view. <i>Multiple Sclerosis and Related Disorders</i> , <b>2015</b> , 4, 460-469	4	77

211	Ultrasound versus magnetic resonance imaging for Morton neuroma: systematic review and meta-analysis. <i>European Radiology</i> , <b>2015</b> , 25, 2254-62	8	52
210	Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 150, 405-13	4.4	28
209	Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials. <i>European Journal of Neurology</i> , <b>2015</b> , 22, 960-6	6	43
208	Fingolimod effect on brain volume loss independently contributes to its effect on disability. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 916-24	5	28
207	Challenges and opportunities in designing clinical trials for neuromyelitis optica. <i>Neurology</i> , <b>2015</b> , 84, 1805-15	6.5	30
206	Validation of 1-year predictive score of long-term response to interferon- $\beta$ in everyday clinical practice multiple sclerosis patients. <i>European Journal of Neurology</i> , <b>2015</b> , 22, 973-80	6	13
205	Long-term assessment of no evidence of disease activity in relapsing-remitting MS. <i>Neurology</i> , <b>2015</b> , 85, 1722-3	6.5	22
204	Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. <i>JAMA Neurology</i> , <b>2015</b> , 72, 1433-41	17.2	50
203	Sativex( $\square$ ) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. <i>Journal of Neurology</i> , <b>2015</b> , 262, 2520-7	5.5	36
202	Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 597-606	15	321
201	Can we measure long-term treatment effects in multiple sclerosis?. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 176-82	15	49
200	Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. <i>EMBO Molecular Medicine</i> , <b>2015</b> , 7, 1513-28	12	115
199	Innovative quantitative testing of hand function in Charcot-Marie-Tooth neuropathy. <i>Journal of the Peripheral Nervous System</i> , <b>2015</b> , 20, 410-4	4.7	7
198	Gray Matter Correlates of Cognitive Performance Differ between Relapsing-Remitting and Primary-Progressive Multiple Sclerosis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0129380	3.7	15
197	Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis. <i>Neurology</i> , <b>2015</b> , 84, 1473-82	6.5	24
196	Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. <i>Neurology</i> , <b>2015</b> , 84, 981-8	6.5	155
195	Reproducibility of T2 * mapping in the human cerebral cortex in vivo at 7 tesla MRI. <i>Journal of Magnetic Resonance Imaging</i> , <b>2015</b> , 42, 290-6	5.6	19
194	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 799-805	2.4	170

193	Remote ischemic postconditioning as a strategy to reduce acute kidney injury during primary PCI: a post-hoc analysis of a randomized trial. <i>International Journal of Cardiology</i> , <b>2014</b> , 177, 500-2	3.2	17
192	Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 214-9	5	37
191	Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. <i>BMC Neurology</i> , <b>2014</b> , 14, 103	3.1	9
190	Defining the clinical course of multiple sclerosis: the 2013 revisions. <i>Neurology</i> , <b>2014</b> , 83, 278-86	6.5	1632
189	Age independently affects myelin integrity as detected by magnetization transfer magnetic resonance imaging in multiple sclerosis. <i>NeuroImage: Clinical</i> , <b>2014</b> , 4, 641-8	5.3	17
188	Radiologically isolated syndrome: 5-year risk for an initial clinical event. <i>PLoS ONE</i> , <b>2014</b> , 9, e90509	3.7	190
187	Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. <i>PLoS ONE</i> , <b>2014</b> , 9, e108205	3.7	82
186	HPV-related oropharyngeal carcinoma with Overt Level II and/or III metastases at presentation: The risk of subclinical disease in ipsilateral levels IB, IV and V. <i>Acta Oncologica</i> , <b>2014</b> , 53, 662-8	3.2	22
185	Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 2168-73	2.4	87
184	Reply: To PMID 24006277. <i>Annals of Neurology</i> , <b>2014</b> , 75, 463-4	9.4	
183	Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3883-91	2.2	151
182	Comment on the letter by Messori et al. (European Journal of Neurology 2013; 20: e131). <i>European Journal of Neurology</i> , <b>2014</b> , 21, e84	6	
181	Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen. <i>Haematologica</i> , <b>2014</b> , 99, 1509-15	6.6	35
180	Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). <i>JAMA Neurology</i> , <b>2014</b> , 71, 954-60	17.2	44
179	6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes. <i>PLoS ONE</i> , <b>2014</b> , 9, e83400	3.7	56
178	Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. <i>Annals of Neurology</i> , <b>2014</b> , 75, 43-9	9.4	195
177	Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy. <i>Neuromuscular Disorders</i> , <b>2014</b> , 24, 201-6	2.9	68
176	MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: yes. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 280-1	5	4

175	Pharmacokinetics of lopinavir determined with an ELISA test in youths with perinatally acquired HIV. <i>Indian Journal of Pediatrics</i> , <b>2014</b> , 81, 856-60	3	1
174	Breast density assessment using a 3T MRI system: comparison among different sequences. <i>PLoS ONE</i> , <b>2014</b> , 9, e99027	3.7	23
173	Defining and scoring response to IFN- $\beta$ in multiple sclerosis. <i>Nature Reviews Neurology</i> , <b>2013</b> , 9, 504-12	15	85
172	Six minute walk test in type III spinal muscular atrophy: a 12month longitudinal study. <i>Neuromuscular Disorders</i> , <b>2013</b> , 23, 624-8	2.9	35
171	Brain atrophy and lesion load predict long term disability in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2013</b> , 84, 1082-91	5.5	209
170	Italian multicentre observational study of the prevalence of CCSVI in multiple sclerosis (CoSMo study): rationale, design, and methodology. <i>Neurological Sciences</i> , <b>2013</b> , 34, 1297-307	3.5	14
169	Response to immunosuppressive treatment predicts outcome in patients with chronic graft-versus-host disease: a single-center analysis of longitudinal data. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 576-83	4.7	1
168	Early neurodevelopmental assessment in Duchenne muscular dystrophy. <i>Neuromuscular Disorders</i> , <b>2013</b> , 23, 451-5	2.9	45
167	MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. <i>Lancet Neurology</i> , <b>2013</b> , 12, 669-76	24.1	190
166	Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials. <i>Neurology</i> , <b>2013</b> , 81, 1215-21	6.5	26
165	Clinical epidemiology of ALS in Liguria, Italy. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , <b>2013</b> , 14, 52-7	3.6	20
164	Identification and validation of a new set of five genes for prediction of risk in early breast cancer. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 9686-702	6.3	13
163	Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1508-17	5	35
162	Scoring treatment response in patients with relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 605-12	5	178
161	Refining response to treatment as defined by the Modified Rio Score. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1246-7	5	31
160	Time to first relapse as an endpoint in multiple sclerosis clinical trials. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 466-74	5	25
159	MRI as a surrogate marker for clinical outcomes in multiple sclerosis <b>2013</b> , 124-132		
158	Quantitative assessment of finger motor impairment in multiple sclerosis. <i>PLoS ONE</i> , <b>2013</b> , 8, e65225	3.7	35

157	24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. <i>PLoS ONE</i> , <b>2013</b> , 8, e52512	3.7	75
156	Atlas-based versus individual-based fiber tracking of the corpus callosum in patients with multiple sclerosis: reliability and clinical correlations. <i>Journal of Neuroimaging</i> , <b>2012</b> , 22, 355-64	2.8	4
155	Modeling the distribution of new MRI cortical lesions in multiple sclerosis longitudinal studies by Sormani MP, Calabrese M, Signori A, Giorgio A, Gallo P, De Stefano N [PLoS One 2011;6(10):e26712. Epub 2011 October 20]. <i>Multiple Sclerosis and Related Disorders</i> , <b>2012</b> , 1, 108	4	10
154	Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients. <i>Journal of Infection and Chemotherapy</i> , <b>2012</b> , 18, 587-90	2.2	3
153	Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, 235-42	4	56
152	Chronic GVHD is associated with lower relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors. <i>Bone Marrow Transplantation</i> , <b>2012</b> , 47, 1474-8	4.4	29
151	Reporting of subgroup analyses from clinical trials. <i>Lancet Neurology, The</i> , <b>2012</b> , 11, 747; author reply 747-8	24.1	11
150	Efficacy and safety of subcutaneous interferon $\beta$ 1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study. <i>Journal of the Neurological Sciences</i> , <b>2012</b> , 312, 97-101	3.2	23
149	Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. <i>Journal of NeuroImmune Pharmacology</i> , <b>2012</b> , 7, 665-72	6.9	28
148	The quality of reports of randomized trials in multiple sclerosis: a review. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 776-81	5	5
147	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 835-42	5	95
146	A parametric model fitting time to first event for overdispersed data: application to time to relapse in multiple sclerosis. <i>Lifetime Data Analysis</i> , <b>2012</b> , 18, 139-56	1.3	3
145	Indirect comparisons of treatment effects in multiple sclerosis. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 1227-8; author reply 1225-6	2.8	
144	A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 825-34	5	70
143	Clinical impact of MEFV mutations in children with periodic fever in a prevalent western European Caucasian population. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1961-5	2.4	51
142	Modelling the distribution of cortical lesions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 229-31	5	9
141	Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010. <i>International Journal of MS Care</i> , <b>2012</b> , 14, 105-14	2.3	16
140	Impairment in explicit visuomotor sequence learning is related to loss of microstructural integrity of the corpus callosum in multiple sclerosis patients with minimal disability. <i>NeuroImage</i> , <b>2011</b> , 57, 495-507	7.9	29

139	Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2011</b> , 17, 541-9	5	47
138	Modeling the distribution of new MRI cortical lesions in multiple sclerosis longitudinal studies. <i>PLoS ONE</i> , <b>2011</b> , 6, e26712	3.7	10
137	A multicentre study of motor functional connectivity changes in patients with multiple sclerosis. <i>European Journal of Neuroscience</i> , <b>2011</b> , 33, 1256-63	3.5	21
136	Comments on "evidence for acute neurotoxicity after chemotherapy". <i>Annals of Neurology</i> , <b>2011</b> , 69, 1064; author reply 1064-5	9.4	
135	Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 1141-50		85
134	Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. <i>Neurology</i> , <b>2011</b> , 77, 250-6	6.5	125
133	Thalamic damage predicts the evolution of primary-progressive multiple sclerosis at 5 years. <i>American Journal of Neuroradiology</i> , <b>2011</b> , 32, 1016-20	4.4	50
132	Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. <i>Multiple Sclerosis Journal</i> , <b>2011</b> , 17, 319-26	5	8
131	Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2011</b> , 17, 1432-40 <sup>5</sup>		17
130	Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach: measuring disability in relapsing-remitting MS. <i>Neurology</i> , <b>2011</b> , 76, 1025; author reply 1025-6	6.5	4
129	Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. <i>Neurology</i> , <b>2011</b> , 77, 1684-90	6.5	79
128	Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs. <i>Multiple Sclerosis Journal</i> , <b>2011</b> , 17, 630-3	5	17
127	MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. <i>Nature Reviews Neurology</i> , <b>2011</b> , 8, 13-21	15	57
126	Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis. <i>PLoS ONE</i> , <b>2011</b> , 6, e19452	3.7	55
125	Risk factors for chronic kidney disease among human immunodeficiency virus-infected patients: A European case control study. <i>Clinical Nephrology</i> , <b>2011</b> , 75, 518-23	2.1	12
124	Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. <i>Bone Marrow Transplantation</i> , <b>2010</b> , 45, 385-91	4.4	46
123	MRI predictors of long-term evolution in amyotrophic lateral sclerosis. <i>European Journal of Neuroscience</i> , <b>2010</b> , 32, 1490-6	3.5	47
122	Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 1490-9	5	22



121	Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. <i>Neurology</i> , <b>2010</b> , 75, 1988-94	6.5	134
120	Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. <i>Neurology</i> , <b>2010</b> , 74, 1868-76	6.5	234
119	Thalamic damage and long-term progression of disability in multiple sclerosis. <i>Radiology</i> , <b>2010</b> , 257, 463-9	6.5	107
118	Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. <i>Neurology</i> , <b>2010</b> , 75, 302-9	6.5	92
117	A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS). <i>Therapeutic Advances in Neurological Disorders</i> , <b>2010</b> , 3, 3-13	6.6	20
116	The daily diary and the questionnaire are not equivalent for the evaluation of bowel habits. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 99-102	3.3	8
115	Assessing changes in relapse rates in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 1414-21	5	81
114	Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. <i>NeuroImage</i> , <b>2010</b> , 50, 446-55	7.9	203
113	Putative predictive parameters for the outcome of laparoscopic splenectomy: a multicenter analysis performed on the Italian Registry of Laparoscopic Surgery of the Spleen. <i>Annals of Surgery</i> , <b>2010</b> , 251, 287-91	7.8	51
112	A phase I/II study of altered fractionated IMRT alone for intermediate T-stage oropharyngeal carcinoma. <i>Strahlentherapie Und Onkologie</i> , <b>2010</b> , 186, 489-95	4.3	11
111	How often do patients ask for the results of their radiological studies?. <i>Insights Into Imaging</i> , <b>2010</b> , 1, 83-85	5.6	14
110	The role of AIRE polymorphisms in melanoma. <i>Clinical Immunology</i> , <b>2010</b> , 136, 96-104	9	21
109	A reassessment of the plateauing relationship between T2 lesion load and disability in MS. <i>Neurology</i> , <b>2009</b> , 73, 1538-42	6.5	32
108	MRI as an outcome in multiple sclerosis clinical trials. <i>Neurology</i> , <b>2009</b> , 73, 1932; author reply 1932-3	6.5	4
107	Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?. <i>Multiple Sclerosis Journal</i> , <b>2009</b> , 15, 1043-7	5	13
106	Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. <i>Annals of Neurology</i> , <b>2009</b> , 65, 268-75	9.4	178
105	Abnormal connectivity of the sensorimotor network in patients with MS: a multicenter fMRI study. <i>Human Brain Mapping</i> , <b>2009</b> , 30, 2412-25	5.9	47
104	Dosimetric predictors of diarrhea during radiotherapy for prostate cancer. <i>Strahlentherapie Und Onkologie</i> , <b>2009</b> , 185, 390-6	4.3	16

103	HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. <i>Bone Marrow Transplantation</i> , <b>2009</b> , 44, 571-7	4.4	39
102	Defining the risk of involvement for each neck nodal level in patients with early T-stage node-positive oropharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 1356-64	4	48
101	Wrist injuries in nonprofessional tennis players: relationships with different grips. <i>American Journal of Sports Medicine</i> , <b>2009</b> , 37, 760-7	6.8	54
100	The Will Rogers phenomenon: the effect of different diagnostic criteria. <i>Journal of the Neurological Sciences</i> , <b>2009</b> , 287 Suppl 1, S46-9	3.2	50
99	Differentiating PFAPA syndrome from monogenic periodic fevers. <i>Pediatrics</i> , <b>2009</b> , 124, e721-8	7.4	109
98	Upper respiratory tract infections and sublingual immunotherapy: preliminary evidence. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2009</b> , 102, 262-3	3.2	9
97	Autologous HSCT Induce a Sustained Inhibition of New MRI Lesions in Severe Refractory Multiple Sclerosis. Long Term Results of a Prospective Multicenter Trial.. <i>Blood</i> , <b>2009</b> , 114, 1221-1221	2.2	
96	Relationship between soluble HLA-G and HLA-A,-B,-C serum levels, and interferon-gamma production after sublingual immunotherapy in patients with allergic rhinitis. <i>Human Immunology</i> , <b>2008</b> , 69, 409-13	2.3	19
95	Carry-over effect on IFN-gamma production induced by allergen-specific immunotherapy. <i>International Immunopharmacology</i> , <b>2008</b> , 8, 1622-5	5.8	10
94	Comparison of three strategies to delineate the bowel for whole pelvis IMRT of prostate cancer. <i>Radiotherapy and Oncology</i> , <b>2008</b> , 88, 95-101	5.3	41
93	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2008</b> , 14, 455-64	5	46
92	Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. <i>Neurology</i> , <b>2008</b> , 70, 1134-40	4.4	52
91	Supervised automatic procedure to identify new lesions in brain MR longitudinal studies of patients with multiple sclerosis. <i>Radiologia Medica</i> , <b>2008</b> , 113, 300-6	6.5	1
90	A three-year, multi-parametric MRI study in patients at presentation with CIS. <i>Journal of Neurology</i> , <b>2008</b> , 255, 683-91	5.5	65
89	Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study. <i>Journal of Neurology</i> , <b>2008</b> , 255, 1378-83	5.5	24
88	Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression. <i>International Journal of Cancer</i> , <b>2008</b> , 123, 1108-16	7.5	33
87	A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 1823-32		135
86	Will Rogers phenomenon in multiple sclerosis. <i>Annals of Neurology</i> , <b>2008</b> , 64, 428-33	9.4	66

85	Body mass index in Th1 and Th2 diseases. <i>Immunology Letters</i> , <b>2008</b> , 117, 119-20	4.1	8
84	Sublingual immunotherapy provides an early increase of interferon-gamma production. <i>Journal of Biological Regulators and Homeostatic Agents</i> , <b>2008</b> , 22, 169-73	0.7	3
83	Incorporating domain knowledge into the fuzzy connectedness framework: application to brain lesion volume estimation in multiple sclerosis. <i>IEEE Transactions on Medical Imaging</i> , <b>2007</b> , 26, 1670-80	11.7	19
82	Dosimetric predictors of laryngeal edema. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 68, 741-9	4	85
81	Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. <i>Journal of the Peripheral Nervous System</i> , <b>2007</b> , 12, 102-7	4.7	84
80	Statistical issues related to the use of MRI data in multiple sclerosis. <i>Journal of Neuroimaging</i> , <b>2007</b> , 17 Suppl 1, 56S-59S	2.8	4
79	A brain magnetization transfer MRI study with a clinical follow up of about four years in patients with clinically isolated syndromes suggestive of multiple sclerosis. <i>Journal of Neurology</i> , <b>2007</b> , 254, 78-83	5.5	15
78	In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. <i>Brain</i> , <b>2007</b> , 130, 2211-9	11.2	130
77	Evaluation of insulin resistance in a cohort of HIV-infected youth. <i>European Journal of Endocrinology</i> , <b>2007</b> , 157, 655-9	6.5	28
76	A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis. <i>American Journal of Neuroradiology</i> , <b>2007</b> , 28, 1659-61	4.4	26
75	A composite score to predict short-term disease activity in patients with relapsing-remitting MS. <i>Neurology</i> , <b>2007</b> , 69, 1230-5	6.5	27
74	Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study. <i>Archives of Neurology</i> , <b>2007</b> , 64, 1163-8		44
73	Evidence for cervical cord tissue disorganisation with aging by diffusion tensor MRI. <i>NeuroImage</i> , <b>2007</b> , 36, 728-35	7.9	47
72	Effect of HLA-Matching on Outcome of Hematopoietic Stem Cell Transplantation from Unrelated Donors: A IBMDR-GITMO Study.. <i>Blood</i> , <b>2007</b> , 110, 3052-3052	2.2	
71	Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. <i>Brain</i> , <b>2006</b> , 129, 2620-7	11.2	132
70	Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. <i>Brain</i> , <b>2006</b> , 129, 2628-34	11.2	111
69	Cervical cord magnetization transfer ratio and clinical changes over 18 months in patients with relapsing-remitting multiple sclerosis: a preliminary study. <i>Multiple Sclerosis Journal</i> , <b>2006</b> , 12, 662-5	5	18
68	Influence of aging on brain gray and white matter changes assessed by conventional, MT, and DT MRI. <i>Neurology</i> , <b>2006</b> , 66, 535-9	6.5	101

67	Self-perceived normality in defecation habits. <i>Digestive and Liver Disease</i> , <b>2006</b> , 38, 103-8	3.3	15
66	BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. <i>Blood</i> , <b>2006</b> , 107, 1591-8	2.2	44
65	Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis. <i>Archives of Neurology</i> , <b>2006</b> , 63, 736-40		30
64	Laparoscopic splenectomy for hematologic diseases: a preliminary analysis performed on the Italian Registry of Laparoscopic Surgery of the Spleen (IRLSS). <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2006</b> , 20, 1214-20	5.2	43
63	The Italian Registry of Laparoscopic Surgery of the Spleen (IRLSS) A retrospective review of 379 patients undergoing laparoscopic splenectomy. <i>Chirurgia Italiana</i> , <b>2006</b> , 58, 697-707		11
62	Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. <i>NeuroImage</i> , <b>2005</b> , 24, 1139-46	7.9	99
61	Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2005</b> , 61, 762-71	4	64
60	The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis. <i>Journal of Neurology</i> , <b>2005</b> , 252, 1455-8	5.5	20
59	The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2005</b> , 11, 447-9	5	20
58	Evidence for progressive gray matter loss in patients with relapsing-remitting MS. <i>Neurology</i> , <b>2005</b> , 65, 1126-8	6.5	69
57	Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study. <i>Archives of Neurology</i> , <b>2005</b> , 62, 578-84		96
56	A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. <i>Blood</i> , <b>2004</b> , 103, 1417-24	2.2	151
55	Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. <i>Neurology</i> , <b>2004</b> , 62, 1432-4	6.5	106
54	Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. <i>Clinical Endocrinology</i> , <b>2004</b> , 61, 138-44	3.4	34
53	Thirteen years of follow-up in patients with adjustable silicone gastric banding for obesity: weight loss and constant rate of late specific complications. <i>Obesity Surgery</i> , <b>2004</b> , 14, 1343-8	3.7	44
52	European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. <i>Archives of Neurology</i> , <b>2004</b> , 61, 1409-12		53
51	Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients. <i>Melanoma Research</i> , <b>2004</b> , 14, 443-8	3.3	24
50	Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , <b>2004</b> , 89, 1238-47	6.6	57

49	MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b. <i>Neurology</i> , <b>2003</b> , 60, 1462-6	6.5	45
48	Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. <i>Brain</i> , <b>2003</b> , 126, 2323-32	11.2	86
47	Age-related changes in conventional, magnetization transfer, and diffusion-tensor MR imaging findings: study with whole-brain tissue histogram analysis. <i>Radiology</i> , <b>2003</b> , 227, 731-8	20.5	121
46	A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose. <i>Bone Marrow Transplantation</i> , <b>2003</b> , 32, 205-11	4.4	21
45	Inter-sequence and inter-imaging unit variability of diffusion tensor MR imaging histogram-derived metrics of the brain in healthy volunteers. <i>American Journal of Neuroradiology</i> , <b>2003</b> , 24, 638-43	4.4	63
44	MR correlates of cerebral atrophy in patients with multiple sclerosis. <i>Journal of Neurology</i> , <b>2002</b> , 249, 1072-7	5.5	74
43	Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , <b>2002</b> , 106, 109-12	3.8	59
42	Involvement of the hypothalamic-pituitary-adrenal axis in children with oligoarticular-onset idiopathic arthritis. <i>Annals of the New York Academy of Sciences</i> , <b>2002</b> , 966, 369-72	6.5	3
41	MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. <i>Neurology</i> , <b>2002</b> , 58, 417-21	6.5	53
40	Irreversible disability and tissue loss in multiple sclerosis: a conventional and magnetization transfer magnetic resonance imaging study of the optic nerves. <i>Archives of Neurology</i> , <b>2002</b> , 59, 250-5		72
39	Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. <i>American Journal of Neuroradiology</i> , <b>2002</b> , 23, 985-8	4.4	131
38	Changes in markers of bone turnover and inflammatory variables during alendronate therapy in pediatric patients with rheumatic diseases. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 1786-92	4.1	28
37	Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. <i>Neurology</i> , <b>2001</b> , 57, 62-8	6.5	139
36	Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. <i>Blood</i> , <b>2001</b> , 98, 3150-5	2.2	111
35	A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis. <i>Journal of Neurology</i> , <b>2001</b> , 248, 215-24	5.5	65
34	Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2001</b> , 70, 494-9	5.5	45
33	Modelling new enhancing MRI lesion counts in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2001</b> , 7, 298-304		26
32	Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2001</b> , 7, 27-31	5	26

31	Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments. <i>Neurology</i> , <b>2001</b> , 57, 1883-5	6.5	15
30	Effects of seasons on magnetic resonance imaging--measured disease activity in patients with multiple sclerosis. <i>Annals of Neurology</i> , <b>2001</b> , 49, 415-6	9.4	7
29	Prevalence of atopy in multiple sclerosis patients: a case-control study. <i>Journal of Neurology</i> , <b>2001</b> , 248, 239-40	5.5	7
28	Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. <i>Journal of Neurology</i> , <b>2000</b> , 247, 960-5	5.5	46
27	The effect of cladribine on T(1) Black hole changes in progressive MS. <i>Journal of the Neurological Sciences</i> , <b>2000</b> , 176, 42-4	3.2	58
26	Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. <i>American Journal of Neuroradiology</i> , <b>2000</b> , 21, 1034-8	4.4	94
25	Reproducibility of magnetization transfer ratio histogram-derived measures of the brain in healthy volunteers. <i>American Journal of Neuroradiology</i> , <b>2000</b> , 21, 133-6	4.4	28
24	Tumor necrosis factor induced adhesion molecule serum concentrations in Henoch-Schleien purpura and pediatric systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2000</b> , 27, 2251-5	4.1	12
23	Increased gut permeability in juvenile chronic arthritides. A multivariate analysis of the diagnostic parameters. <i>Clinical and Experimental Rheumatology</i> , <b>2000</b> , 18, 773-8	2.2	43
22	Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>1999</b> , 66, 465-9	5.5	17
21	Reproducibility of brain MRI lesion volume measurements in multiple sclerosis using a local thresholding technique: effects of formal operator training. <i>European Neurology</i> , <b>1999</b> , 41, 226-30	2.1	9
20	Short-term evolution of individual enhancing MS lesions studied with magnetization transfer imaging. <i>Magnetic Resonance Imaging</i> , <b>1999</b> , 17, 979-84	3.3	25
19	MRI enhancing lesion frequency from patients with MS enrolled in the placebo arms of clinical trials or in natural history studies. <i>Magnetic Resonance Imaging</i> , <b>1999</b> , 17, 1236-7	3.3	
18	Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images. <i>Journal of Neurology</i> , <b>1999</b> , 246, 920-5	5.5	10
17	Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. <i>Journal of the Neurological Sciences</i> , <b>1999</b> , 163, 74-80	3.2	65
16	Correlations between clinical and MRI involvement in multiple sclerosis: assessment using T(1), T(2) and MT histograms. <i>Journal of the Neurological Sciences</i> , <b>1999</b> , 171, 121-9	3.2	65
15	A comparison of MR imaging with fast-FLAIR, HASTE-FLAIR, and EPI-FLAIR sequences in the assessment of patients with multiple sclerosis. <i>American Journal of Neuroradiology</i> , <b>1999</b> , 20, 1931-8	4.4	10
14	Interscanner variation in brain MR lesion load measurements in multiple sclerosis using conventional spin-echo, rapid relaxation-enhanced, and fast-FLAIR sequences. <i>American Journal of Neuroradiology</i> , <b>1999</b> , 20, 133-7	4.4	19

13	The effect of repositioning on brain MRI lesion load assessment in multiple sclerosis: reliability of subjective quality criteria. <i>Journal of Neurology</i> , <b>1998</b> , 245, 273-5	5.5	16
12	How does brain MRI lesion volume change on serial scans in patients with multiple sclerosis?. <i>Magnetic Resonance Imaging</i> , <b>1998</b> , 16, 1181-3	3.3	3
11	Brain MRI lesion volume measurement reproducibility is not dependent on the disease burden in patients with multiple sclerosis. <i>Magnetic Resonance Imaging</i> , <b>1998</b> , 16, 1185-9	3.3	3
10	Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. <i>Neurology</i> , <b>1998</b> , 50, 238-44	6.5	77
9	Intraobserver and interobserver variability in measuring changes in lesion volume on serial brain MR images in multiple sclerosis. <i>American Journal of Neuroradiology</i> , <b>1998</b> , 19, 685-7	4.4	5
8	Sensitivity of enhanced MR in multiple sclerosis: effects of contrast dose and magnetization transfer contrast. <i>American Journal of Neuroradiology</i> , <b>1998</b> , 19, 1863-7	4.4	9
7	Differences in tumor necrosis factor-alpha soluble receptor serum concentrations between patients with Henoch-Schleien purpura and pediatric systemic lupus erythematosus: pathogenetic implications. <i>Journal of Rheumatology</i> , <b>1998</b> , 25, 361-5	4.1	12
6	<sup>99m</sup> Tc-white cell scanning to detect gut inflammation in children with inflammatory bowel diseases or spondyloarthropathies. <i>Clinical and Experimental Rheumatology</i> , <b>1998</b> , 16, 327-34	2.2	11
5	Timing of surgery related to menstrual cycle and prognosis of premenopausal women with breast cancer. <i>Anticancer Research</i> , <b>1997</b> , 17, 787-90	2.3	8
4	Predictive factors for outcome in invasive bladder cancer treated with alternating chemoradiotherapy. <i>Cancer Journal From Scientific American</i> , <b>1997</b> , 3, 213-23		3
3	Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>1996</b> , 55, 243-7	2.4	33
2	Breakthrough SARS-CoV-2 infections in MS patients on disease modifying therapies		2
1	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies		6